Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19

Kow et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001441
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
Review of sample size calculations in ivermectin RCTs, showing that existing RCTs are very underpowered.
Reviews covering ivermectin for COVID-19 include1-38.
Kow et al., 6 Aug 2021, peer-reviewed, 2 authors.
This PaperIvermectinAll
{ 'indexed': {'date-parts': [[2023, 9, 18]], 'date-time': '2023-09-18T04:35:25Z', 'timestamp': 1695011725354}, 'reference-count': 24, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '5', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.1097/mjt.0000000000001441', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 13]], 'date-time': '2021-08-13T13:55:18Z', 'timestamp': 1628862918000}, 'page': 'e616-e619', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving ' 'Ivermectin for the treatment of COVID-19', 'prefix': '10.1097', 'volume': '28', 'author': [ { 'given': 'Chia Siang', 'family': 'Kow', 'sequence': 'first', 'affiliation': [ { 'name': 'School of Pharmacy, Monash University Malaysia Bandar Sunway, ' 'Selangor, Malaysia'}, { 'name': 'School of Postgraduate Studies, International Medical ' 'University, Kuala Lumpur, Malaysia'}]}, { 'given': 'Syed S.', 'family': 'Hasan', 'sequence': 'additional', 'affiliation': [ { 'name': 'School of Applied Sciences, University of Huddersfield, ' 'Huddersfield, United Kingdom'}, { 'name': 'School of Biomedical Sciences and Pharmacy University of ' 'Newcastle, Callaghan, Australia'}]}], 'member': '276', 'published-online': {'date-parts': [[2021, 9]]}, 'reference': [ { 'key': 'R1-20230917', 'doi-asserted-by': 'crossref', 'first-page': '533', 'DOI': '10.1016/S1473-3099(20)30120-1', 'article-title': 'An interactive web-based dashboard to track COVID-19 in real time', 'volume': '20', 'author': 'Dong', 'year': '2020', 'journal-title': 'Lancet Infect Dis.'}, { 'key': 'R2-20230917', 'article-title': 'The use of remdesivir for the management of patients with ' 'moderate-to-severe COVID-19: a systematic review', 'author': 'Thiruchelvam', 'year': '2021', 'journal-title': 'Expert Rev Anti Infect Ther.'}, { 'key': 'R3-20230917', 'doi-asserted-by': 'crossref', 'DOI': '10.1080/17476348.2021.1925546', 'article-title': 'Does methylprednisolone reduce the mortality risk in hospitalized ' 'COVID-19 patients? A meta-analysis of randomized control trials', 'author': 'Hasan', 'year': '2021', 'journal-title': 'Expert Rev Respir Med.'}, { 'key': 'R4-20230917', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s43440-021-00245-z', 'article-title': 'The association between the use of ivermectin and mortality in patients ' 'with COVID-19: a meta-analysis', 'author': 'Kow', 'year': '2021', 'journal-title': 'Pharmacol Rep.'}, { 'key': 'R5-20230917', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antivir Res'}, { 'key': 'R6-20230917', 'doi-asserted-by': 'crossref', 'first-page': 'e3001162', 'DOI': '10.1371/journal.pbio.3001162', 'article-title': 'The methodological quality of 176,620 RCTs published between 1966 and ' '2018 reveals a positive trend but also an urgent need for improvement', 'volume': '19', 'author': 'Vinkers', 'year': '2021', 'journal-title': 'PLoS Biol.'}, { 'key': 'R7-20230917', 'doi-asserted-by': 'crossref', 'first-page': '107', 'DOI': '10.1016/j.ijid.2020.09.1470', 'article-title': 'Use of hydroxychloroquine and chloroquine in COVID-19: how good is the ' 'quality of RCTs?', 'volume': '101', 'author': 'Mazhar', 'year': '2020', 'journal-title': 'Int J Infect Dis.'}, { 'key': 'R8-20230917', 'doi-asserted-by': 'crossref', 'first-page': 'S12', 'DOI': '10.1016/j.chest.2020.03.010', 'article-title': 'Sample size estimation in clinical research: from RCTs to observational ' 'studies', 'volume': '158', 'author': 'Wang', 'year': '2020', 'journal-title': 'Chest'}, { 'key': 'R9-20230917', 'doi-asserted-by': 'crossref', 'first-page': 'e434', 'DOI': '10.1097/MJT.0000000000001402', 'article-title': 'Ivermectin for prevention and treatment of COVID-19 infection: a ' 'systematic review, meta-analysis, and trial sequential analysis to ' 'inform clinical guidelines', 'volume': '28', 'author': 'Bryant', 'year': '2021', 'journal-title': 'Am J Ther.'}, { 'key': 'R10-20230917', 'doi-asserted-by': 'crossref', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'article-title': 'Dexamethasone in hospitalized patients with covid-19', 'volume': '384', 'author': 'Horby', 'year': '2021', 'journal-title': 'N Engl J Med.'}, { 'key': 'R11-20230917', 'doi-asserted-by': 'crossref', 'first-page': '220', 'DOI': '10.1186/s12874-020-01101-z', 'article-title': 'Statistical design of Phase II/III clinical trials for testing ' 'therapeutic interventions in COVID-19 patients', 'volume': '20', 'author': 'Rai', 'year': '2020', 'journal-title': 'BMC Med Res Methodol'}, { 'key': 'R12-20230917', 'doi-asserted-by': 'crossref', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19: a randomized clinical trial', 'volume': '325', 'author': 'López-Medina', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': 'R14-20230917', 'first-page': '10', 'article-title': 'Ivermectin as a potential treatment for mild to moderate COVID-19—a ' 'double blind randomized placebo-controlled trial', 'volume': '2021', 'author': 'Ravikirti', 'year': '2021', 'journal-title': 'medRxiv'}, { 'key': 'R15-20230917', 'doi-asserted-by': 'crossref', 'first-page': '235', 'DOI': '10.1080/20477724.2021.1890887', 'article-title': 'Phase 2 randomized study on chloroquine, hydroxychloroquine or ' 'ivermectin in hospitalized patients with severe manifestations of ' 'SARS-CoV-2 infection', 'volume': '115', 'author': 'Galan', 'year': '2021', 'journal-title': 'Pathog Glob Health'}, { 'key': 'R16-20230917', 'article-title': 'Efficacy and safety of ivermectin and hydroxychloroquine in patients ' 'with severe COVID-19. A randomized controlled trial', 'author': 'Gonzalez', 'year': '2021', 'journal-title': 'Preprint Medrxiv.'}, { 'key': 'R17-20230917', 'article-title': 'Controlled randomized clinical trial on using ivermectin with ' 'doxycycline for treating COVID-19 patients in Baghdad, Iraq', 'author': 'Hashim', 'year': '2020', 'journal-title': 'Preprint Medrxiv.'}, { 'key': 'R18-20230917', 'doi-asserted-by': 'crossref', 'first-page': '411', 'DOI': '10.1186/s12879-021-06104-9', 'article-title': 'Evaluation of the effectiveness and safety of adding ivermectin to ' 'treatment in severe COVID-19 patients', 'volume': '21', 'author': 'Okumus', 'year': '2021', 'journal-title': 'BMC Infect Dis'}, { 'key': 'R19-20230917', 'article-title': 'Ivermectin as an adjunct treatment for hospitalized adult COVID-19 ' 'patients: a randomized multi-center clinical trial', 'author': 'Niaee', 'year': '2020', 'journal-title': 'Preprint Res Square'}, { 'key': 'R20-20230917', 'article-title': 'Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a ' 'randomised, controlled, open-label, platform trial', 'author': 'Horby', 'year': '2021', 'journal-title': 'Preprint Medrxiv.'}, { 'key': 'R21-20230917', 'doi-asserted-by': 'crossref', 'first-page': '605', 'DOI': '10.1016/S0140-6736(21)00149-5', 'article-title': 'Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): ' 'a randomised, controlled, open-label, platform trial', 'volume': '397', 'year': '2021', 'journal-title': 'Lancet'}, { 'key': 'R22-20230917', 'doi-asserted-by': 'crossref', 'first-page': '2030', 'DOI': '10.1056/NEJMoa2022926', 'article-title': 'Effect of hydroxychloroquine in hospitalized patients with covid-19', 'volume': '383', 'author': 'Horby', 'year': '2020', 'journal-title': 'N Engl J Med.'}, { 'key': 'R23-20230917', 'first-page': '55', 'article-title': 'Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a ' 'randomised, controlled, open-label, platform trial', 'volume': '2021', 'author': 'Horby', 'year': '2021', 'journal-title': 'Preprint Medrxiv.'}, { 'key': 'R24-20230917', 'doi-asserted-by': 'crossref', 'first-page': '2049', 'DOI': '10.1016/S0140-6736(21)00897-7', 'article-title': 'Convalescent plasma in patients admitted to hospital with COVID-19 ' '(RECOVERY): a randomised controlled, open-label, platform trial', 'volume': '397', 'year': '2021', 'journal-title': 'Lancet'}, { 'key': 'R25-20230917', 'doi-asserted-by': 'crossref', 'first-page': '1345', 'DOI': '10.1016/S0140-6736(20)32013-4', 'article-title': 'Lopinavir-ritonavir in patients admitted to hospital with COVID-19 ' '(RECOVERY): a randomised, controlled, open-label, platform trial', 'volume': '396', 'year': '2020', 'journal-title': 'Lancet'}], 'container-title': 'American Journal of Therapeutics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001441', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 17]], 'date-time': '2023-09-17T04:19:01Z', 'timestamp': 1694924341000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001441'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 8, 6]]}, 'references-count': 24, 'journal-issue': {'issue': '5', 'published-online': {'date-parts': [[2021]]}}, 'URL': 'http://dx.doi.org/10.1097/MJT.0000000000001441', 'relation': {}, 'ISSN': ['1075-2765'], 'subject': [], 'published': {'date-parts': [[2021, 8, 6]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit